Expanding the Horizons of Healthcare Monitoring – Real World Data & Evidence!

Expanding the Horizons of Healthcare Monitoring – Real World Data & Evidence!

The lifecycle of drug development, right from moment of conception till the time its approved for widespread usage, is an extremely long & complex one. The amount of data generated through trials or acquired from various points of collection, which is required to be analysed during this process is humongous. For a drug to be effective, the patient data which forms the foundation of its development, must closely reflect the conditions of the demographic or section of people it is intended for.   This is where, Real World Data (RWD)…

Read More

Real World Evidence is key for pharma organizations in drug development- 5th Edition MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference

Real World Evidence is key for pharma organizations in drug development- 5th Edition MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference

5th Edition MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference (Time Zone – EST) to be held on 19th – 22nd October 2021 will host industry giants like Sarepta Therapeutics, Idorsia Pharmaceuticals, Food and Drug Administration (FDA), AveXis, Rafael Pharmaceuticals, PicnicHealth, Dedalus Group, RTI Health Solutions, Bluebird Bio, Seagen, Takeda, Takeda Pharmaceuticals, Novartis, OM1 and many more. The global real-world evidence market is valued at 612.0 million in 2017 and projected to reach USD 1,348.1 million by 2023, at a CAGR of 14.3%. The growth of this…

Read More

Speaker Interview with Elodie Baumfeld Andre 2nd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress

Speaker Interview with  Elodie Baumfeld Andre 2nd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress

Boston, September 9, 2019 – MarketsandMarkets recently interviewed Elodie Baumfeld Andre, Senior Director, Epidemiology Strategy Lead, Worldwide Medical & Safety, Pfizer regarding 2nd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress taking place on October 24 – 25, 2019 at DoubleTree by Hilton Boston-Downtown . Elodie Baumfeld Andre is the Epidemiology Strategy Lead within the Worldwide Medical & Safety group at Pfizer. In this role, Elodie’s focus is on generating Real World Evidence (RWE) to support regulatory decision-making and driving continued innovation by implementing novel clinical designs and developing operating models. She is…

Read More

Technologies Transforming Real-World Evidence (RWE) Evidence in the Pharmaceutical Industry

Technologies Transforming Real-World Evidence (RWE) Evidence in the Pharmaceutical Industry

As new drugs are emerging every day, it is very important to ensure that the patients get right and effective treatment. One such step can be taken from Real World Evidence (RWE). In simple words, Real World Evidence means data and information collected outside of a clinical trial. This data can be electronic medical records, medical charts or other medical claims to assess patient outcomes. It is made sure that the patient’s identity is removed from the previous data to maintain the patient’s privacy. However, today’s real-world evidence data is…

Read More